ArriVent Biopharma (Series B)

Funding Details
Awarder
Inbox
Date Award
March 27, 2023
Vertical
Biopharmaceuticals
Funding URL
View Funding Page
Funding Amount:
$155,000,000

Company Info
Founders
Bing Yao
Company Description
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
Market
Oncology
Location
Newton Square, PA, USA
Coinvestors
AIHC Capital, Boyu Capital, Catalio Capital Management, General Catalyst Partners, HBM Healthcare Investments, Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, OrbiMed Advisors, Sequoia China, Shanghai Healthcare Capital, Sirona Capital, Sofinnova Ventures, Terra Magnum Capital Partners, Unicorn Capital Partners Limited

Links